Colon cancer survival with herbal medicine and vitamins combined with standard therapy in a whole-systems approach: Ten-year follow-up data analyzed with marginal structural models and propensity score methods

Integrative Cancer Therapies

Volumn 10, Issue 3, 2011, Pages 240-259

  McCulloch, Michael ^a,b   Broffman, Michael ^a   Van Der Laan, Mark ^b   Hubbard, Alan ^b   Kushi, Lawrence ^c   Abrams, Donald I ^d   Gao, Jin ^e   Colford Jr , John M ^b  

^a Pine Street Foundation ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

chemotherapy; Chinese herbal medicine; colon cancer; marginal structural models; propensity score; radiotherapy; survival; vitamins

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CURCUMIN; FISH OIL; FOLIC ACID; HERBACEOUS AGENT; MELATONIN; MILK PROTEIN; PROBIOTIC AGENT; PROPOLIS; ROYAL JELLY; SOYBEAN PROTEIN; THYMUS EXTRACT; UBIDECARENONE;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARTILAGE; CHINESE MEDICINE; COLON CANCER; CONTROLLED STUDY; FOLLOW UP; HERBAL MEDICINE; HUMAN; LACTOBACILLUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TEA; VITAMIN SUPPLEMENTATION;

AGED; COHORT STUDIES; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DIET; DRUGS, CHINESE HERBAL; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HERBAL MEDICINE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; NEOPLASM STAGING; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMINS;

EID: 84855363459     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735411406539     Document Type: Review

References (113)

1. Jemal A, Siegel R, et al. Cancer statistics. A Cancer Journal for Clinicians. 2008 ; 58 (2). 71-96
2. EllenhornJDCullinaneCA. 2007. Colon, rectal and anal cancers. Cancer Management: A Multidisciplinary Approach.
3. R. Pazdur, L. Coia, R, W. J. Hoskins and L. D. Wagman. Lawrence, Kansas, CMP Medica LLC. http://www.cancernetwork.com/cancer-management/colorectal/ article/10165/1802621. Accessed May 8, 2011.
4. Swanson RS, Compton CC, Stewart AK, et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003 ; 10: 65-71
5. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 ; 351: 1731-1740
6. Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol. 1989 ; 7: 1419-1426 (Pubitemid 19245111)
7. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991 ; 9: 1967-1972
8. Rabeneck L, El-Serag HB, Davila JA, et al. Outcomes of colorectal cancer in the United States: no change in survival (1986-1997). Am J Gastroenterol. 2003 ; 98: 471-477 (Pubitemid 36232402)
9. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993 ; 306: 752-755 (Pubitemid 23080053)
10. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 ; 18: 2938-2947 (Pubitemid 30644117)
11. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000 ; 355: 1041-1047 (Pubitemid 30162806)
12. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000 ; 18: 136-147 (Pubitemid 30036347)
13. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000 ; 343: 905-914
14. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 ; 350: 2343-2351 (Pubitemid 38702845)
15. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004 ; 22: 23-30 (Pubitemid 41095110)
16. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 ; 22: 229-237 (Pubitemid 41095086)
17. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 ; 352: 2696-2704 (Pubitemid 41007824)
18. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 ; 351: 337-345 (Pubitemid 38944402)
19. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 ; 350: 2335-2342 (Pubitemid 38702844)
20. Mok TS, Yeo W, Johnson PJ, et al. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol. 2007 ; 18: 768-774 (Pubitemid 46523283)
21. Meng ZQ, Xu YY, Liu LM, et al. Clinical evaluation of integration of transcatheter arterial chemoembolization and traditional Chinese medicine in treating metastatic liver cancer [in Chinese]. Zhong Xi Yi Jie He Xue Bao. 2003 ; 1: 187 233-188
22. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004 ; 291: 2720-2726 (Pubitemid 38725421)
23. Smith CA, Coyle ME. Recruitment and implementation strategies in randomised controlled trials of acupuncture and herbal medicine in women's health. Complement Ther Med. 2006 ; 14: 81-86 (Pubitemid 43210580)
24. Patterson RE, Neuhouser ML, Hedderson MM, et al. Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med. 2002 ; 8: 477-485 (Pubitemid 34994542)
25. Fouladbakhsh JM, Stommel M, Given BA, et al. Predictors of use of complementary and alternative therapies among patients with cancer. Oncol Nurs Forum. 2005 ; 32: 1115-1122
26. Lawsin C, DuHamel K, Itzkowitz SH, et al. Demographic, medical, and psychosocial correlates to CAM use among survivors of colorectal cancer. Support Care Cancer. 2007 ; 15: 557-564 (Pubitemid 46570790)
27. West SG, Duan N, Pequegnat W, et al. Alternatives to the randomized controlled trial. Am J Public Health. 2008 ; 98: 1359-1366
28. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001 ; 96: 440-448
29. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000 ; 56: 779-788
30. Mortimer KM, Neugebauer R, van der Laan M, et al. An application of model-fitting procedures for marginal structural models. Am J Epidemiol. 2005 ; 162: 382-388 (Pubitemid 41389720)
31. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000 ; 11: 550-560 (Pubitemid 30660034)
32. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983 ; 70: 41-55
33. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984 ; 79: 516-524
34. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003 ; 14: 680-686 (Pubitemid 40417015)
35. Cole SR, Hernan MA, Margolick JB, et al. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol. 2005 ; 162: 471-478 (Pubitemid 41191433)
36. Petersen ML, Wang Y, van der Laan MJ, et al. Assessing the effectiveness of antiretroviral adherence interventions: using marginal structural models to replicate the findings of randomized controlled trials. J Acquir Immune Defic Syndr. 2006 ; 43: S96 - S103 (Pubitemid 44885647)
37. Delaney JA, Daskalopoulou SS, Suissa S. Traditional versus marginal structural models to estimate the effectiveness of beta-blocker use on mortality after myocardial infarction. Pharmacoepidemiol Drug Saf. 2000 ; 18: 1-6
38. Yamaguchi T, Ohashi Y. Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part I: structural nested models and marginal structural models to test and estimate treatment arm effects. Stat Med. 2004 ; 23: 1991-2003 (Pubitemid 38968024)
39. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007 ; 4: e297
40. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol. 1992 ; 21: 837-841
41. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging. J Natl Cancer Inst. 2004 ; 96: 1420-1425 (Pubitemid 39429665)
42. Cappell MS. Reducing the incidence and mortality of colon cancer: mass screening and colonoscopic polypectomy. Gastroenterol Clin North Am. 2008 ; 37: 129 vii - 160 viii
43. AJCC Cancer Staging Manual. Philadelphia, PA: Lippincott-Raven ; 1997:
44. SEER Program: Comparative Staging Guide for Cancer. Bethesda, MD: National Institutes of Health ; 1993:
45. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B Stat Methodol. 1972 ; 34: 187-220
46. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 1979 ; 7: 1-26
47. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985 ; 39: 33-38
48. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999 ; 150: 327-333 (Pubitemid 29383480)
49. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997 ; 127 (8, pt 2). 757-763 (Pubitemid 27446562)
50. Becker SO, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J. 2002 ; 2: 358-377
51. O'Connell JB, Maggard MA, Liu JH, et al. Do young colon cancer patients have worse outcomes?. World J Surg. 2004 ; 28: 558-562 (Pubitemid 38802791)
52. Lefebvre G, Delaney JA, Platt RW. Impact of mis- specification of the treatment model on estimates from a marginal structural model. Stat Med. 2008 ; 27: 3629-3642
53. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008 ; 168: 656-664
54. Helyer LK, Chin S, Chui BK, et al. The use of complementary and alternative medicines among patients with locally advanced breast cancer: a descriptive study. BMC Cancer. 2006 ; 6: 39
55. Dejardin O, Bouvier AM, Faivre J, et al. Access to care, socioeconomic deprivation and colon cancer survival. Aliment Pharmacol Ther. 2008 ; 27: 940-949 (Pubitemid 351537655)
56. Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007 ; 110: 660-669 (Pubitemid 47106157)
57. Du XL, Meyer TE, Franzini L. Meta-analysis of racial disparities in survival in association with socioeconomic status among men and women with colon cancer. Cancer. 2007 ; 109: 2161-2170 (Pubitemid 46801545)
58. Batty GD, Kivimaki M, Gray L, et al. Cigarette smoking and site-specific cancer mortality: testing uncertain associations using extended follow-up of the original Whitehall study. Ann Oncol. 2008 ; 19: 996-1002 (Pubitemid 351627320)
59. Chao A, Thun MJ, Jacobs EJ, et al. Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. J Natl Cancer Inst. 2000 ; 92: 1888-1896 (Pubitemid 32036919)
60. Colangelo LA, Gapstur SM, Gann PH, et al. Cigarette smoking and colorectal carcinoma mortality in a cohort with long-term follow-up. Cancer. 2004 ; 100: 288-293 (Pubitemid 38063636)
61. Botteri E, Iodice S, Raimondi S, et al. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology. 2008 ; 134: 388-395
62. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007 ; 298: 754-764 (Pubitemid 47263158)
63. Ananda S, Field KM, Kosmider S, et al. Patient age and comorbidity are major determinants of adjuvant chemotherapy use for stage III colon cancer in routine clinical practice. J Clin Oncol. 2008 ; 26: 4516-4517
64. Macpherson H. Pragmatic clinical trials. Complement Ther Med. 2004 ; 12: 136-140 (Pubitemid 39618841)
65. Meta-Analysis Group In Cancer. J Clin Oncol. 1998 ; 16: 3537-3541
66. Lo Bello L, Pistone G, Restuccia S, et al. 5-Fluorouracil alone versus 5-fluorouracil plus folinic acid in the treatment of colorectal carcinoma: meta-analysis. Int J Clin Pharmacol Ther. 2000 ; 38: 553-562
67. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002 ; 20: 1491-1498 (Pubitemid 34260527)
68. Xiang D, Wang D, He Y, et al. Caffeic acid phenethyl ester induces growth arrest and apoptosis of colon cancer cells via the beta-catenin/T-cell factor signaling. Anticancer Drugs. 2006 ; 17: 753-762 (Pubitemid 44310172)
69. Russo A, Cardile V, Sanchez F, et al. Chilean propolis: antioxidant activity and antiproliferative action in human tumor cell lines. Life Sci. 2004 ; 76: 545-558 (Pubitemid 39535666)
70. Shimizu K, Das SK, Hashimoto T, et al. Artepillin C in Brazilian propolis induces G(0)/G(1) arrest via stimulation of Cip1/p21 expression in human colon cancer cells. Mol Carcinog. 2005 ; 44: 293-299 (Pubitemid 41780753)
71. Liao HF, Chen YY, Liu JJ, et al. Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, and metastasis. J Agric Food Chem. 2003 ; 51: 7907-7912
72. Majumdar AP, Kodali U, Jaszewski R. Chemopreventive role of folic acid in colorectal cancer. Front Biosci. 2004 ; 9: 2725-2732
73. Strohle A, Wolters M, Hahn A. Folic acid and colorectal cancer prevention: molecular mechanisms and epidemiological evidence (Review). Int J Oncol. 2005 ; 26: 1449-1464
74. Estensen RD, Levy M, Klopp SJ, et al. N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps. Cancer Lett. 1999 ; 147: 109-114
75. Sakano K, Takahashi M, Kitano M, et al. Suppression of azoxymethane-induced colonic premalignant lesion formation by coenzyme Q10 in rats. Asian Pac J Cancer Prev. 2006 ; 7: 599-603
76. Du B, Jiang L, Xia Q, et al. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy. 2006 ; 52: 23-28 (Pubitemid 43004433)
77. Patel BB, Sengupta R, Qazi S, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer. 2008 ; 122: 267-273 (Pubitemid 350234711)
78. Su CC, Lin JG, Li TM, et al. Curcumin-induced apoptosis of human colon cancer colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3. Anticancer Res. 2006 ; 26: 4379-4389
79. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett. 2007 ; 255: 170-181 (Pubitemid 47268637)
80. Fish-oil supplementation reduces intestinal hyperproliferation in persons at risk for colon cancer. Nutr Rev. 1993 ; 51: 241-243
81. Lindner MA. A fish oil diet inhibits colon cancer in mice. Nutr Cancer. 1991 ; 15: 1-11
82. Coleman LJ, Landstrom EK, Royle PJ, et al. A diet containing alpha-cellulose and fish oil reduces aberrant crypt foci formation and modulates other possible markers for colon cancer risk in azoxymethane-treated rats. J Nutr. 2002 ; 132: 2312-2318 (Pubitemid 34851668)
83. Zhou GD, Popovic N, Lupton JR, et al. Tissue-specific attenuation of endogenous DNA I-compounds in rats by carcinogen azoxymethane: possible role of dietary fish oil in colon cancer prevention. Cancer Epidemiol Biomarkers Prev. 2005 ; 14: 1230-1235 (Pubitemid 40656472)
84. Parodi PW. A role for milk proteins and their peptides in cancer prevention. Curr Pharm Des. 2007 ; 13: 813-828 (Pubitemid 46585506)
85. Bargahi A, Rabbani-Chadegani A. Angiogenic inhibitor protein fractions derived from shark cartilage. Biosci Rep. 2008 ; 28: 15-21
86. Miller DR, Anderson GT, Stark JJ, et al. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998 ; 16: 3649-3655 (Pubitemid 28506780)
87. Hong KJ, Dunn DM, Shen CL, et al. Effects of Ganoderma lucidum on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells. Phytother Res. 2004 ; 18: 768-770 (Pubitemid 39481699)
88. Lu H, Kyo E, Uesaka T, et al. A water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia suppresses azoxymethane-induction of colon cancers in male F344 rats. Oncol Rep. 2003 ; 10: 375-379
89. Lu H, Kyo E, Uesaka T, et al. Prevention of development of N,N'-dimethylhydrazine-induced colon tumors by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male ICR mice. Int J Mol Med. 2002 ; 9: 113-117
90. Lu H, Uesaka T, Katoh O, et al. Prevention of the development of preneoplastic lesions, aberrant crypt foci, by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male F344 rats. Oncol Rep. 2001 ; 8: 1341-1345 (Pubitemid 33758743)
91. Lee MY, Lin HY, Cheng F, et al. Isolation and characterization of new lactam compounds that inhibit lung and colon cancer cells from adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) bran. Food Chem Toxicol. 2008 ; 46: 1933-1939
92. Hynes JB, Kumar A, Tomazic A, et al. Synthesis of 5-chloro-5,8-dideaza analogues of folic acid and aminopterin targeted for colon adenocarcinoma. J Med Chem. 1987 ; 30: 1515-1519 (Pubitemid 17114838)
93. Sugiyama T, Sadzuka Y. Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. Biochim Biophys Acta. 2003 ; 1653: 47-59 (Pubitemid 37487647)
94. Cerea G, Vaghi M, Ardizzoia A, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res. 2003 ; 23: 1951-1954 (Pubitemid 36750873)
95. Kakuda T. Neuroprotective effects of the green tea components theanine and catechins. Biol Pharm Bull. 2002 ; 25: 1513-1518 (Pubitemid 39663661)
96. Nathan PJ, Lu K, Gray M, et al. The neuropharmacology of L-theanine(N-ethyl-l-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother. 2006 ; 6: 21-30 (Pubitemid 44964090)
97. Ioannides C, Hall DE, Mulder DE, et al. A comparison of the protective effects of N-acetyl-cysteine and S-carboxymethylcysteine against paracetamol-induced hepatotoxicity. Toxicology. 1983 ; 28: 313-321 (Pubitemid 14237212)
98. Sprague CL, Elfarra AA. Protection of rats against 3-butene-1, 2-diol-induced hepatotoxicity and hypoglycemia by N-acetyl-l-cysteine. Toxicol Appl Pharmacol. 2005 ; 207: 266-274 (Pubitemid 41207919)
99. Varma PS, Aruna K, Rukkumani R, et al. Alcohol and thermally oxidized PUFA induced oxidative stress: role of N-acetyl cysteine. Ital J Biochem. 2004 ; 53: 10-15
100. Berend N. Inhibition of bleomycin lung toxicity by N-acetyl cysteine in the rat. Pathology. 1985 ; 17: 108-110 (Pubitemid 15105043)
101. Gon Y, Hashimoto S, Nakayama T, et al. N-acetyl-l-cysteine inhibits bleomycin-induced interleukin-8 secretion by bronchial epithelial cells. Respirology. 2000 ; 5: 309-313 (Pubitemid 32049491)
102. Trizna Z, Schantz SP, Hsu TC. Effects of N-acetyl-l-cysteine and ascorbic acid on mutagen-induced chromosomal sensitivity in patients with head and neck cancers. Am J Surg. 1991 ; 162: 294-298
103. Takimoto M, Sakurai T, Kodama K, et al. Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy [in Japanese]. Gan To Kagaku Ryoho. 1982 ; 9: 116-121 (Pubitemid 12158009)
104. Okada K, Yamada S, Kawashima Y, et al. Cell injury by antineoplastic agents and influence of coenzyme Q10 on cellular potassium activity and potential difference across the membrane in rat liver cells. Cancer Res. 1980 ; 40: 1663-1667 (Pubitemid 10102014)
105. Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007 ; 97: 1028-1034 (Pubitemid 47587008)
106. Kim SH, Lee HJ, Kim JS, et al. Protective effect of an herbal preparation (HemoHIM) on radiation-induced intestinal injury in mice. J Med Food. 2009 ; 12: 1353-1358
107. Jagetia GC. Radioprotective potential of plants and herbs against the effects of ionizing radiation. J Clin Biochem Nutr. 2007 ; 40: 74-81 (Pubitemid 46623808)
108. Takeda T, Kamiura S, Kimura T. Effectiveness of the herbal medicine daikenchuto for radiation-induced enteritis. J Altern Complement Med. 2008 ; 14: 753-755
109. Tian YP, Wang QC. Rectal radiation injuries treated by Shen Ling Bai Zhu powders combined with rectal administration of western drugs [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 ; 28: 159-160
110. Sener G, Jahovic N, Tosun O, et al. Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats. Life Sci. 2003 ; 74: 563-572 (Pubitemid 37410348)
111. Bincoletto C, Eberlin S, Figueiredo CA, et al. Effects produced by royal jelly on haematopoiesis: relation with host resistance against Ehrlich ascites tumour challenge. Int Immunopharmacol. 2005 ; 5: 679-688 (Pubitemid 40248323)
112. Salazar-Olivo LA, Paz-Gonzalez V. Screening of biological activities present in honeybee (Apis mellifera) royal jelly. Toxicol In Vitro. 2005 ; 19: 645-651 (Pubitemid 40719539)
113. Beardsley TR, Pierschbacher M, Wetzel GD, et al. Induction of T-cell maturation by a cloned line of thymic epithelium (TEPI). Proc Natl Acad Sci U S A. 1983 ; 80: 6005-6009 (Pubitemid 14228232)